Liquidia Corporation (LQDA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Morrisville, NC, アメリカ. 現CEOは Roger A. Jeffs.
LQDA を有する IPO日 2018-07-26, 170 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $3.41B.
Liquidia Corporation is a biopharmaceutical company founded in 2004 and headquartered in Morrisville, North Carolina, focused on developing and commercializing innovative treatments for unmet patient needs in the United States. The company's lead product candidate, YUTREPIA, is an inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension. In addition to its proprietary pipeline, Liquidia manufactures and distributes generic treprostinil injection throughout the U.S. market, combining both innovative drug development and generic pharmaceutical distribution capabilities.
